Aegis initiated coverage on shares of Avinger (NASDAQ:AVGR) in a research report report published on Thursday morning, The Fly reports. The brokerage issued a buy rating on the medical device company’s stock.

AVGR has been the topic of a number of other reports. ValuEngine downgraded shares of Avinger from a buy rating to a hold rating in a research report on Wednesday, September 4th. Zacks Investment Research upgraded shares of Avinger from a hold rating to a buy rating and set a $2.00 price target on the stock in a research report on Tuesday, August 6th.

Shares of NASDAQ AVGR remained flat at $$1.13 during mid-day trading on Thursday. 236,787 shares of the stock traded hands, compared to its average volume of 298,432. The stock has a market capitalization of $7.39 million, a PE ratio of -0.03 and a beta of 1.58. The company has a current ratio of 1.45, a quick ratio of 1.17 and a debt-to-equity ratio of 0.46. Avinger has a one year low of $1.04 and a one year high of $15.60. The company has a 50 day simple moving average of $1.55 and a two-hundred day simple moving average of $1.19.

Avinger (NASDAQ:AVGR) last announced its quarterly earnings results on Wednesday, July 31st. The medical device company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.90) by $0.03. The business had revenue of $2.32 million for the quarter. Avinger had a negative net margin of 258.12% and a negative return on equity of 230.13%. On average, equities research analysts anticipate that Avinger will post -2.61 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Avinger stock. Spark Investment Management LLC purchased a new stake in Avinger Inc (NASDAQ:AVGR) during the first quarter, according to its most recent filing with the SEC. The firm purchased 103,043 shares of the medical device company’s stock, valued at approximately $98,000. Spark Investment Management LLC owned 0.21% of Avinger at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.51% of the company’s stock.

About Avinger

Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.

Featured Story: What is a closed-end mutual fund (CEF)?

The Fly

Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with's FREE daily email newsletter.